z-logo
open-access-imgOpen Access
Serum level of endostatin and digital ulcers in systemic sclerosis patients
Author(s) -
Gigante Antonietta,
Margiotta Domenico,
Navarini Luca,
Barbano Biagio,
Gasperini Maria L.,
D'Agostino Claudia,
Amoroso Antonio,
Afeltra Antonella,
Rosato Edoardo
Publication year - 2018
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12882
Subject(s) - endostatin , medicine , gastroenterology , odds ratio , confidence interval , receiver operating characteristic , gangrene , surgery , angiogenesis
Patients with systemic sclerosis (SSc) are at a high risk of the development of ischaemic digital ulcers (DUs) that can be complicated with infections, gangrene, and osteomyelitis. The aim of this study is to evaluate the role of endostatin in scleroderma DUs.In total, 90 SSc patients were enrolled in this study. Serum endostatin levels and DU assessment were determined in all SSc patients. The serum levels of endostatin significantly increased with progression of capillaroscopic damage ( P < .01). The serum levels of endostatin are significantly ( P < .05) higher in SSc patients with new DUs than in SSc patients without new DUs (127 ± 31.1 ng/mL vs 116.3 ± 39.7 ng/mL). The Receiver Operating Characteristic (ROC) curves demonstrated good accuracy of new DU prediction for the serum level of endostatin (0.70, P < .01 [95% confidence interval (CI) 0.59‐0.81]). Using a cut‐off value of 116 ng/mL, the odds ratio was 2.609 (CI 1.075‐6.330, P < .05). The serum levels of endostatin are significantly ( P < .01) higher in SSc patients with infected DUs than in SSc patients without infected DUs (139.2 [114.6‐340.91] ng/mL vs 117.5 [64.3‐163.9] ng/mL). Serum levels of endostatin are higher in patients with DUs, especially in those with infected DUs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here